DANBURY, CT, August 17, 2011 – IMS Health today announced the launch of IMS MIDAS Biosimilarsä, a market measurement tool that enables clients to assess the value of treatments and guide commercial decisions in this rapidly developing segment of the global biologics marketplace. The new offering establishes an industry-verified standard market definition for the biosimilars segment, enabling consistent analyses across geographies, therapies and manufacturers in more than 70 countries.
“Innovative products and expanding indications are fueling new patient treatment options and greater demand for biologics around the world. At the same time, the prospects for biosimilars are growing as payers look for cost-effective alternatives to specialty drugs,” said Alan Sheppard, principal, Global Generics, IMS. “For companies looking to expand in this space or to evaluate the competition, IMS can help track the performance and potential of existing biosimilars, and determine how the segment is changing over time – all key to ensuring effective portfolio strategies and maximizing return on investment.”
According to the IMS Institute for Healthcare Informatics, global spending on biosimilars is expected to exceed $2 billion annually by 2015, up from $311 million last year. The U.S. biosimilar approval pathway, included in the Affordable Care Act, is expected to result in biosimilars entering the U.S. market by 2014. European countries also will see additional types of biosimilars introduced during this period, including monoclonal antibodies. Currently, more than 300 monoclonal antibodies are in development for 200+ indications, including oncology, inflammatory and autoimmune diseases, metabolic and central nervous system disorders, and cardiovascular disease.
In addition to tracking individual products from launch through their lifecycle, IMS MIDAS Biosimilars also can be used to monitor local markets’ response to legislation affecting the segment. As a fully integrated global resource with flexible delivery options, users can easily incorporate data into their existing market monitoring reports and dashboards. Added Sheppard, “This offering builds on our unique array of global assets and knowledge to provide a clear picture of a market where we see considerable growth and opportunity.”
IMS MIDAS Biosimilars is the latest addition to the company’s MIDAS portfolio of products, the industry-leading resource for measuring the global pharmaceutical market.
Additional information is available at www.imshealth.com/biosimilars, or by e-mailing IMS at biosimilars@imshealth.com.
About IMS Health
IMS Health is the leading provider of information services for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and consulting platforms to help clients better understand the performance and value of medicines. With a presence in 100+ countries and more than 55 years of industry experience, IMS serves leading decision makers in healthcare, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at http://www.imshealth.com
